Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma

Talal El Zarif,Karl Semaan,Marc Eid,Ji-Heui Seo,Simon Garinet,Matthew P. Davidsohn,Pranshu Sahgal,Brad Fortunato,John Canniff,Amin H. Nassar,Sarah Abou Alaiwi,Ziad Bakouny,Gitanjali Lakshminarayanan,Hunter Savignano,Kevin Lyons,Sayed Matar,Atef Ali,Eddy Saad,Renee Maria Saliby,Paulo Cordeiro,Ziwei Zhang,Nourhan El Ahmar,Yasmin Nabil Laimon,Chris Labaki,Valisha Shah,Dory Freeman,Jillian O’Toole,Gwo-Shu Mary Lee,Justin Hwang,Mark Pomerantz,Sabina Signoretti,Eliezer M. Van Allen,Wanling Xie,Jacob E. Berchuck,Srinivas R. Viswanathan,David A. Braun,Toni K. Choueiri,Matthew L. Freedman,Sylvan C. Baca
DOI: https://doi.org/10.1016/j.celrep.2024.114350
IF: 8.8
2024-06-14
Cell Reports
Abstract:El Zarif et al. present a comprehensive epigenomic characterization of sarcomatoid renal cell carcinoma (sRCC). They establish associations between FOSL1 gene expression and clinical outcomes to immunotherapy in RCC. In a proof of concept, they developed an epigenomic liquid biopsy technique that enables the detection of sRCC in blood.
cell biology
What problem does this paper attempt to address?